Tag Archives: Sanofi

September, 2016

August, 2016

  • 22 August

    FDA Delays Decision on Sanofi’s Diabetes Drug

    Paris, France – August 19, 2016 – Sanofi announced today that it has submitted updated information on the pen delivery device as part of the New Drug Application (NDA) for the investigational once-daily fixed-ratio combination of basal insulin glargine 100 Units/mL and GLP-1 receptor agonist lixisenatide for the treatment of …

July, 2016

May, 2016

  • 11 May

    Cigna Signs Value Contracts for New PCSK9 Inhibitor Cholesterol Drugs

    BLOOMFIELD, Conn., 11 May, 2016 – Cigna (NYSE: CI) has entered into new value-based contracts with both Amgen and Sanofi/Regeneron for their PCSK9 inhibitors for commercial business. The contracts modify the cost of the new cholesterol-lowering drugs Repatha  TM and Praluent ® based on how well customers respond to the medications, …

  • 2 May

    Medivation Rejects Sanofi’s Takeover Bid

    SAN FRANCISCO, CA  — (Marketwired) — 04/29/16 — Medivation, Inc. (NASDAQ: MDVN) today announced that its Board of Directors, after consultation with its financial and legal advisors, unanimously determined that the unsolicited proposal from Sanofi to acquire Medivation for $52.50 per share in cash substantially undervalues Medivation and is not …

April, 2016

  • 29 April

    Sanofi Offers $9.3 Billion to Buy Cancer Drugmaker Medivation

    Paris, April 28, 2016 – Sanofi today announced that it has sent a letter to Medivation, Inc., in which it makes a non-binding proposal to acquire Medivation for $52.50 per share. This would represent an all-cash transaction valued at approximately $9.3 billion.[1] Combining Sanofi and Medivation represents a compelling strategic …

March, 2016

  • 16 March

    Sanofi Enters $2.3 Billion Deal with DiCE Molecules

    Paris, France and San Francisco – March 16, 2016 – Sanofi and DiCE Molecules, a newly-launched, privately held company developing a next generation approach to small molecule drug discovery, today announced a five-year global collaboration to discover potential new therapeutics for up to 12 targets that encompass all disease areas …

  • 11 March

    Regeneron and Sanofi’s RA Drug Meets Primary Endpoint in Late-Stage Trial

    TARRYTOWN, N.Y. and PARIS, March 11, 2016 /PRNewswire/ — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that a Phase 3 monotherapy study met its primary endpoint demonstrating that sarilumab was superior to adalimumab (marketed by AbbVie as HUMIRA®) in improving signs and symptoms in patients with active rheumatoid arthritis …

January, 2016